iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Cetera Advisors LLC

Cetera Advisors LLC raised its position in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 221.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,797 shares of the financial services provider’s stock after acquiring an additional 24,648 shares during the period. Cetera Advisors LLC’s holdings in iShares NASDAQ Biotechnology Index were worth $3,818,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. CHURCHILL MANAGEMENT Corp raised its position in shares of iShares NASDAQ Biotechnology Index by 223.2% in the fourth quarter. CHURCHILL MANAGEMENT Corp now owns 1,801,330 shares of the financial services provider’s stock valued at $192,328,000 after buying an additional 1,244,066 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd raised its position in shares of iShares NASDAQ Biotechnology Index by 175.5% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 635,875 shares of the financial services provider’s stock valued at $212,132,000 after buying an additional 405,091 shares in the last quarter. Lockheed Martin Investment Management Co. raised its position in shares of iShares NASDAQ Biotechnology Index by 200.0% in the fourth quarter. Lockheed Martin Investment Management Co. now owns 329,400 shares of the financial services provider’s stock valued at $35,170,000 after buying an additional 219,600 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of iShares NASDAQ Biotechnology Index by 199.9% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 313,485 shares of the financial services provider’s stock valued at $33,470,000 after buying an additional 208,963 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI raised its position in shares of iShares NASDAQ Biotechnology Index by 159.9% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 294,237 shares of the financial services provider’s stock valued at $31,416,000 after buying an additional 181,036 shares in the last quarter. Institutional investors own 27.28% of the company’s stock.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at $107.54 on Wednesday. iShares NASDAQ Biotechnology Index has a 1 year low of $94.20 and a 1 year high of $119.30. The firm has a market cap of $9,460.00, a P/E ratio of 3.55 and a beta of 1.37.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/ishares-nasdaq-biotechnology-index-ibb-shares-bought-by-cetera-advisors-llc.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply